LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 540 participants.
Also called NCT07288398
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 540 participants
- Sponsor
- Registry
-
NCT07288398 -
2025-522475-28-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Austria, Brazil, Bulgaria, Czechia, France, Germany, Hungary, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07288398. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-03 (actual); primary completion 2028-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
- Acronym
- LEVEL-2
- Condition
- Pulmonary Hypertension Associated With HFpEF
- Intervention (Drug)
- TNX-103
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tenax Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct07288398- Content hash
eeb3e787137fc5f249518d394e31a932169d9519d1ad4b4c72ba22f8e8970d5b